Alpha-lipoic acid protects against 6-hydroxydopamine-induced neurotoxicity in a rat model of hemi-parkinsonism

Brain Research

Volumn 1505, Issue , 2013, Pages 68-74

  Jalali Nadoushan, Mohammadreza ^a   Roghani, Mehrdad ^a  

^a SHAHED UNIVERSITY   (Iran)

Author keywords

6 hydroxydopamine; Alpha lipoic acid; Oxidative stress; Parkinson's disease

Indexed keywords

APOMORPHINE; CREMOPHOR; MALONALDEHYDE; NITRITE; OXIDOPAMINE; SUPEROXIDE DISMUTASE; THIOCTIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; LIPID PEROXIDATION; MALE; MESENCEPHALON; NERVE CELL; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA PARS COMPACTA;

ADRENERGIC AGENTS; ANIMALS; APOMORPHINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FUNCTIONAL LATERALITY; MALONDIALDEHYDE; NEURONS; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS; ROTATION; SUBSTANTIA NIGRA; THIOCTIC ACID;

RATTUS;

EID: 84875230889     PISSN: 00068993     EISSN: 18726240     Source Type: Journal    
DOI: 10.1016/j.brainres.2013.01.054     Document Type: Article

References (42)

1. A.A. Abdin, and N.I. Sarhan Intervention of mitochondrial dysfunction-oxidative stress-dependent apoptosis as a possible neuroprotective mechanism of alpha-lipoic acid against rotenone-induced parkinsonism and L-dopa toxicity Neurosci. Res. 71 2011 387 395
2. H.A. Aly, D.A. Lightfoot, and H.A. El-Shemy Modulatory role of lipoic acid on lipopolysaccharide-induced oxidative stress in adult rat Sertoli cells in vitro Chem. Biol. Interact. 182 2009 112 118
3. M. Astiz, M.J. de Alaniz, and C.A. Marra The oxidative damage and inflammation caused by pesticides are reverted by lipoic acid in rat brain Neurochem. Int. 61 2012 1231 1241
4. T. Baluchnejadmojarad, M. Roghani, and M. Mafakheri Neuroprotective effect of silymarin in 6-hydroxydopamine hemi-parkinsonian rat: involvement of estrogen receptors and oxidative stress Neurosci. Lett. 480 2010 206 210
5. T. Baluchnejadmojarad, and M. Roghani Chronic epigallocatechin-3-gallate ameliorates learning and memory deficits in diabetic rats via modulation of nitric oxide and oxidative stress Behav. Brain Res. 224 2011 305 310
6. M.M. Bradford A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding Anal. Biochem. 72 1976 248 254
7. P. Chaudhary, G. Marracci, X. Yu, D. Galipeau, B. Morris, and D. Bourdette Lipoic acid decreases inflammation and confers neuroprotection in experimental autoimmune optic neuritis J. Neuroimmunol. 233 2011 90 96
8. S. Chen, and W. Le Neuroprotective therapy in Parkinson disease Am. J. Ther. 13 2006 445 457
9. H.T. Chng, L.S. New, A.H. Neo, C.W. Goh, E.R. Browne, and E.C. Chan Distribution study of orally administered lipoic acid in rat brain tissues Brain Res. 1251 2009 80 86
10. B.J. Connell, and T.M. Saleh Co-administration of apocynin with lipoic acid enhances neuroprotection in a rat model of ischemia/reperfusion Neurosci. Lett. 507 2012 43 46
11. J.P. Covy, and B.I. Giasson alpha-Synuclein, leucine-rich repeat kinase-2, and manganese in the pathogenesis of Parkinson disease Neurotoxicology 32 2011 622 629
12. D.P. De Araujo, F. Lobato Rde, J.R. Cavalcanti, L.R. Sampaio, P.V. Araujo, M.C. Silva, K.R. Neves, M.M. Fonteles, F.C. Sousa, and S.M. Vasconcelos The contributions of antioxidant activity of lipoic acid in reducing neurogenerative progression of Parkinson's disease: a review Int. J. Neurosci. 121 2011 51 57
13. P. Foley, and P. Riederer Influence of neurotoxins and oxidative stress on the onset and progression of Parkinson's disease J. Neurol. 247 Suppl. 2 2000 II82 II94
14. H. Fujita, M. Shiosaka, T. Ogino, Y. Okimura, T. Utsumi, E.F. Sato, R. Akagi, M. Inoue, K. Utsumi, and J. Sasaki Alpha-lipoic acid suppresses 6-hydroxydopamine-induced ROS generation and apoptosis through the stimulation of glutathione synthesis but not by the expression of heme oxygenase-1 Brain Res. 1206 2008 1 12
15. P.J. Garcia Ruiz, M.J. Catalan, and J.M. Fernandez Carril Initial motor symptoms of Parkinson disease Neurologist 17 2011 S18 S20
16. S. Guo, J. Yan, T. Yang, X. Yang, E. Bezard, and B. Zhao Protective effects of green tea polyphenols in the 6-OHDA rat model of Parkinson's disease through inhibition of ROS-NO pathway Biol. Psychiatry 62 2007 1353 1362
17. N. Hattori Etiology and pathogenesis of Parkinson's disease: from mitochondrial dysfunctions to familial Parkinson's disease Rinsho Shinkeigaku 44 2004 241 262
18. C. Henchcliffe, and M.F. Beal Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis Nat. Clin. Pract. Neurol. 4 2008 600 609
19. L. Holmquist, G. Stuchbury, K. Berbaum, S. Muscat, S. Young, K. Hager, J. Engel, and G. Munch Lipoic acid as a novel treatment for Alzheimer's disease and related dementias Pharmacol. Ther. 113 2007 154 164
20. C.K. Hwang, and H.S. Chun Isoliquiritigenin isolated from licorice Glycyrrhiza uralensis prevents 6-hydroxydopamine-induced apoptosis in dopaminergic neurons Biosci. Biotechnol. Biochem. 76 2012 536 543
21. M.M. Iravani, and P. Jenner Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation J. Neural Transm. 118 2011 1661 1690
22. J. Lotharius, and P. Brundin Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein Nat. Rev. Neurosci. 3 2002 932 942
23. A. Maczurek, K. Hager, M. Kenklies, M. Sharman, R. Martins, J. Engel, D.A. Carlson, and G. Munch Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer's disease Adv. Drug Delivery Rev. 60 2008 1463 1470
24. D. Malinska, and K. Winiarska Lipoic acid: characteristics and therapeutic application Postepy Hig. Med. Dosw. (Online) 59 2005 535 543
25. J. Miklossy, D.D. Doudet, C. Schwab, S. Yu, E.G. McGeer, and P.L. McGeer Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys Exp. Neurol. 197 2006 275 283
26. X. Mu, G. He, Y. Cheng, X. Li, B. Xu, and G. Du Baicalein exerts neuroprotective effects in 6-hydroxydopamine-induced experimental parkinsonism in vivo and in vitro Pharmacol. Biochem. Behav. 92 2009 642 648
27. G. Paxinos, and C. Watson The Rat Brain in Stereotaxic Coordinates 2nd ed. 1986 Academic Press San Diego
28. C.D. Pederzolli, A.P. Rosa, A.S. de Oliveira, J.G. Coelho, L. Becker Dda, G.R. Dalazen, T.B. Moraes, and C.S. Dutra-Filho Neuroprotective role of lipoic acid against acute toxicity of N-acetylaspartic acid Mol. Cell. Biochem. 344 2010 231 239
29. M. Roghani, A. Niknam, M.R. Jalali-Nadoushan, Z. Kiasalari, M. Khalili, and T. Baluchnejadmojarad Oral pelargonidin exerts dose-dependent neuroprotection in 6-hydroxydopamine rat model of hemi-parkinsonism Brain Res. Bull. 82 2010 279 283
30. A.H. Schapira Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease Neurology 72 2009 S44 S50
31. A.H. Schapira, and P. Jenner Etiology and pathogenesis of Parkinson's disease Mov. Disord. 26 2011 1049 1055
32. A. Schober Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP Cell Tissue Res. 318 2004 215 224
33. R.K. Schwarting, and J.P. Huston Behavioral and neurochemical dynamics of neurotoxic meso-striatal dopamine lesions Neurotoxicology 18 1997 689 708
34. R.M. Shapiro, S.D. Glick, and N.A. Camarota A two-population model of rat rotational behavior: effects of unilateral nigrostriatal 6-hydroxydopamine on striatal neurochemistry and amphetamine-induced rotation Brain Res. 426 1987 323 331
35. J.K. Soczynska, S.H. Kennedy, C.S. Chow, H.O. Woldeyohannes, J.Z. Konarski, and R.S. McIntyre Acetyl-L-carnitine and alpha-lipoic acid: possible neurotherapeutic agents for mood disorders? Expert Opin. Invest.Drugs 17 2008 827 843
36. K. Sriram, and J.P. O'Callaghan Divergent roles for tumor necrosis factor-alpha in the brain J. Neuroimmune Pharmacol. 2 2007 140 153
37. F. Stocchi, and S. Marconi Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio) Clin. Neuropharmacol. 33 2010 198 203
38. O. Von Bohlen und Halbach, A. Schober, and K. Krieglstein Genes, proteins, and neurotoxins involved in Parkinson's disease Prog. Neurobiol. 73 2004 151 177
39. I. Ybot-Gorrin, F. Vivancos-Matellano, J.R. Chacon-Pena, H. Alonso-Navarro, and F.J. Jimenez-Jimenez Assessment of Parkinson disease: what do we need to show neuroprotection? Neurologist 17 2011 S21 S29
40. C.G. Yuan, L. He, X.L. Xue, Y.T. Shi, and X.H. Bi Effect of alpha-lipoic acid on the apoptosis of PC12 cells induced by 6-hydroxydopamine Shi Yan Sheng Wu Xue Bao 34 2001 65 70
41. S.A. Zaitone, D.M. Abo-Elmatty, and A.A. Shaalan Acetyl-l-carnitine and alpha-lipoic acid affect rotenone-induced damage in nigral dopaminergic neurons of rat brain, implication for Parkinson's disease therapy Pharmacol. Biochem. Behav. 100 2012 347 360
42. F. Zhou, J.Y. Wu, X.L. Sun, H.H. Yao, J.H. Ding, and G. Hu Iptakalim alleviates rotenone-induced degeneration of dopaminergic neurons through inhibiting microglia-mediated neuroinflammation Neuropsychopharmacology 32 2007 2570 2580